159 related articles for article (PubMed ID: 38417292)
1. Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial.
Werner B; Sjoquist KM; Espinoza D; Yip S; Chang G; Cummins MM; Mileshkin L; Ananda S; Shannon C; Friedlander M; Warton K; Ford CE
Transl Oncol; 2024 May; 43():101914. PubMed ID: 38417292
[TBL] [Abstract][Full Text] [Related]
2. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Sjoquist KM; Espinoza D; Mileshkin L; Ananda S; Shannon C; Yip S; Goh J; Bowtell D; Harrison M; Friedlander ML
Gynecol Oncol; 2021 May; 161(2):374-381. PubMed ID: 33637349
[TBL] [Abstract][Full Text] [Related]
3. Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer.
Werner B; Yuwono N; Duggan J; Liu D; David C; Srirangan S; Provan P; ; DeFazio A; Arora V; Farrell R; Lee YC; Warton K; Ford C
Gynecol Oncol; 2021 Sep; 162(3):720-727. PubMed ID: 34454680
[TBL] [Abstract][Full Text] [Related]
4. Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy.
Matsumae T; Kodama T; Myojin Y; Maesaka K; Sakamori R; Takuwa A; Oku K; Motooka D; Sawai Y; Oshita M; Nakabori T; Ohkawa K; Miyazaki M; Tanaka S; Mita E; Tawara S; Yakushijin T; Nozaki Y; Hagiwara H; Tahata Y; Yamada R; Hikita H; Tatsumi T; Takehara T
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884434
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
6. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.
Hansen MKG; Smerdel MP; Waldstrøm M; Andersen RF; Adimi P; Jakobsen A; Steffensen KD
Cancer Chemother Pharmacol; 2020 Dec; 86(6):751-759. PubMed ID: 33067703
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up.
Boons G; Vandamme T; Mariën L; Lybaert W; Roeyen G; Rondou T; Papadimitriou K; Janssens K; Op de Beeck B; Simoens M; Demey W; Dero I; Van Camp G; Peeters M; Op de Beeck K
Clin Cancer Res; 2022 Jan; 28(2):338-349. PubMed ID: 34759042
[TBL] [Abstract][Full Text] [Related]
9. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
Mehra N; Dolling D; Sumanasuriya S; Christova R; Pope L; Carreira S; Seed G; Yuan W; Goodall J; Hall E; Flohr P; Boysen G; Bianchini D; Sartor O; Eisenberger MA; Fizazi K; Oudard S; Chadjaa M; Macé S; de Bono JS
Eur Urol; 2018 Sep; 74(3):283-291. PubMed ID: 29500065
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR-TKI treatment in advanced non-small cell lung cancer.
Zheng J; Wang Y; Hu C; Zhu M; Ii J; Lin C; Lu C; Dou Y; Zhao C; Zhang Y; Wu D; Li L; Tang H; He T; Pan C; Han R; He Y
Thorac Cancer; 2022 Nov; 13(22):3162-3173. PubMed ID: 36193794
[TBL] [Abstract][Full Text] [Related]
11. Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Magbanua MJM; Ahmed Z; Sayaman RW; Brown Swigart L; Hirst GL; Yau C; Wolf DM; Li W; Delson AL; Perlmutter J; Pohlmann P; Symmans WF; Yee D; Hylton NM; Esserman LJ; DeMichele AM; Rugo HS; van 't Veer LJ
Clin Cancer Res; 2024 Mar; ():. PubMed ID: 38470545
[TBL] [Abstract][Full Text] [Related]
12. ctDNA from body fluids is an adequate source for
Pérez-Barrios C; Sánchez-Herrero E; Garcia-Simón N; Barquín M; Clemente MB; Provencio M; Romero A
Clin Chem Lab Med; 2021 Jun; 59(7):1221-1229. PubMed ID: 33691348
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer.
Balgkouranidou I; Chimonidou M; Milaki G; Tsarouxa EG; Kakolyris S; Welch DR; Georgoulias V; Lianidou ES
Br J Cancer; 2014 Apr; 110(8):2054-62. PubMed ID: 24642624
[TBL] [Abstract][Full Text] [Related]
14. Cell-free DNA in human follicular fluid as a biomarker of embryo quality.
Scalici E; Traver S; Molinari N; Mullet T; Monforte M; Vintejoux E; Hamamah S
Hum Reprod; 2014 Dec; 29(12):2661-9. PubMed ID: 25267787
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.
Li BT; Drilon A; Johnson ML; Hsu M; Sima CS; McGinn C; Sugita H; Kris MG; Azzoli CG
Ann Oncol; 2016 Jan; 27(1):154-9. PubMed ID: 26487589
[TBL] [Abstract][Full Text] [Related]
16. Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer.
Carrasco R; Ingelmo-Torres M; Gómez A; Trullas R; Roldán FL; Ajami T; Moreno D; Rodríguez-Carunchio L; Alcaraz A; Izquierdo L; Mengual L
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233035
[TBL] [Abstract][Full Text] [Related]
17. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients.
Valpione S; Gremel G; Mundra P; Middlehurst P; Galvani E; Girotti MR; Lee RJ; Garner G; Dhomen N; Lorigan PC; Marais R
Eur J Cancer; 2018 Jan; 88():1-9. PubMed ID: 29175734
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108.
Jordan K; Luetkens T; Gog C; Killing B; Arnold D; Hinke A; Stahl M; Freier W; Rüssel J; Atanackovic D; Hegewisch-Becker S
Eur J Cancer; 2016 Aug; 63():127-34. PubMed ID: 27314448
[TBL] [Abstract][Full Text] [Related]
19. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
[TBL] [Abstract][Full Text] [Related]
20. Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
Sumanasuriya S; Seed G; Parr H; Christova R; Pope L; Bertan C; Bianchini D; Rescigno P; Figueiredo I; Goodall J; Fowler G; Flohr P; Mehra N; Neeb A; Rekowski J; Eisenberger M; Sartor O; Oudard S; Geffriaud-Ricouard C; Ozatilgan A; Chadjaa M; Macé S; Lord C; Baxter J; Pettitt S; Lambros M; Sharp A; Mateo J; Carreira S; Yuan W; de Bono JS
Eur Urol; 2021 Aug; 80(2):243-253. PubMed ID: 34103179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
